stockportfolio.pro
Hemab Therapeutics Holdings, Inc. (COAG)
Healthcare · Biotechnology · NasdaqGS
Hemab Therapeutics Holdings, Inc. revenue & earnings — last 2 fiscal years
| Metric | 2024 | 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Gross profit | — | — |
| Net income | $-48.71M | $-63.91M |
| Net margin | — | — |
Source: Hemab Therapeutics Holdings, Inc. SEC filings (10-K).
Explore 2 years of Hemab Therapeutics Holdings, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track COAG in your portfolio →
Hemab Therapeutics Holdings, Inc. financial history by metric
About Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
Hemab Therapeutics Holdings, Inc. — frequently asked questions
What is Hemab Therapeutics Holdings, Inc.'s revenue?
Hemab Therapeutics Holdings, Inc. (COAG) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Hemab Therapeutics Holdings, Inc. profitable?
No — COAG reported a net loss of $-63.91M in fiscal 2025.
What is COAG's P/E ratio?
Hemab Therapeutics Holdings, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Hemab Therapeutics Holdings, Inc. have?
As of fiscal year 2025, COAG carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Hemab Therapeutics Holdings, Inc.'s market cap?
Hemab Therapeutics Holdings, Inc. (COAG) has a market capitalization of about $1.25B, based on the latest data in our nightly-refreshed cache.
When does Hemab Therapeutics Holdings, Inc.'s fiscal year end?
COAG's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Hemab Therapeutics Holdings, Inc.'s official SEC filings (10-K and 10-Q), covering 2 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.